Venkatakrishnan et al (2000) reported that in ovarian cancer cells the signal through CXCR1 and CXCR2 by IL-8 transactivated EGF receptor, which is an effective therapeutic target of many EGF receptor inhibitors in NSCLC. This evidence concerns the gene CXCR2 and ovarian cancer.